The bioreductive activation of nitroheterocyclic drugs causes the formation of adducts to cellular macromolecules. We refer to this process as binding. Binding is maximal in the absence of oxygen, and is markedly inhibited as the concentration of oxygen increases; thus, detection of the bound adducts provides an assay signal which increases as the oxygen concentration decreases (Varghese et al., 1976; Chapman, 1979; Koch et al., 1984) . Drug binding is therefore an assay for hypoxia, and has been measured in a number of ways: radioactive drug binding allows detection by several different types of radioactivity assays (Varghese et al., 1976; Chapman et al., 1983; Urtasun et al., 1985; Rasey et al., 1987; Parliament et al., 1992) , fluorine-containing drug binding allows detection by magnetic resonance spectroscopy or imaging (Raleigh et al., 1984) and antigenic properties of the drug adducts allow secondary detection by antibodies (Raleigh et al., 1987; Hodgkiss et al., 1991; Lord et al., 1993) .
The last technique has potential for a very high degree of spatial resolution, and allows assays such as the microscopic distribution of adducts in tissue sections or flow cytometric analysis of individual cells (Hodgkiss et al., 1991) . Although both polyclonal and monoclonal antibodies have been developed against various adducts of 2-nitroimidazole drugs (Raleigh et al., 1987; Hodgkiss et al., 1991; Lord et al., 1993) , it has not been shown that this technique can provide a quantitative assessment of the number of adducts present. In fact, one might expect this not to be the case since the adducts appear to be formed throughout the entire intracellular environment (Lord et al., 1993) , probably at cysteine residues of intracellular proteins (Raleigh and Koch, 1990) . It is known that the intracellular concentration of adducts can easily be several hundred micromolar -e.g. after a non-toxic drug exposure of 1I00 M for 3 h in nitrogen (Koch, 1990 (Koch, 1990; Franko and Koch, 1984; Franko et al., 1987; Cobb et al., 1989 Cobb et al., , 1992 (Cobb et al., 1992; Workman, 1992; Joseph et al., 1994 (Koch, 1990) .
We have shown that binding of etanidazole conforms much more closely to the ideal hypoxia detector described above (Koch, 1990; Koch et al., 1993) . However, etanidazole is very polar, and tends to form most adducts with acidsoluble cellular molecules (Koch, 1990 (Lord et al., 1993) . Monoclonal antibodies which recognise cellular adducts of the drug were found to be highly specific (Lord et al., 1993) . The present study continues this characterisation using the same two cell lines (WNRE and 9L) which previously had been shown to have the most variability in oxygen dependent binding of misonidazole, and using a new monoclonal antibody, ELK3-51, with significantly higher affinity allowing the use of much lower drug concentrations. -(2,2,3,3,3-pentafluoropropyl) Evans and Koch, 1994) Koch, 1984) . The dishes were removed from the incubator, cooled to 0-4°C, and their medium was replaced with fresh medium (with or without EF5 as required), first as a rinse (1 ml) which was simply aspirated and then as the actual medium used for the experiment (also 1 ml). Dishes were placed in leakproof aluminium chambers which were connected to a manifold allowing the gas phase of the chambers to be exchanged for the desired oxygen concentration in a series of gas exchanges taking approximately 30 min. The confinement of cells to the central area of the dish, and the use of a small volume of medium allows very rapid equilibration of the gas and liquid phase to improve the control of oxygen concentration (Koch, 1984) . After gas exchange, the chambers were immersed in a 37°C water bath, for rapid warming, dried, and transferred to a 37°C warm room. To prevent minor gradients of oxygen or other nutrients or metabolites, the chambers were also shaken gently (1 Hz, 2.5 cm stroke).
Materials and methods

Drug synthesis
In some experiments 9L cells were obtained directly from tumours (see accompanying manuscript). They were dissociated using previously described methods (Howell and Koch, 1980; Evans and Koch, 1994 ).
EF5 binding: radioactivity assay Binding of radioactive nitroheterocyclics after incubation under defined experimental conditions was assessed as described previously . Briefly, the dishes were removed from the chambers, then medium containing EF5 was replaced with non-drug-containing medium in a series of rinses, the cells were removed from the dishes with trypsin, trypsin was inactivated with serum-containing medium, and the cell number was determined via a particle counter (Coulter). The cells were lysed with 5% trichloroacetic acid and radioactive counts in the acid-soluble vs acid-precipitable component were determined with standard liquid scintillation techniques using a Packard 1900 TR counter. The uniformity of the cell samples required no corrections for quenching with 14C-label. The scintillation fluid was Ecolite (ICN). EF5 binding is equally distributed between acid-soluble and -insoluble fractions under all conditions studied (data not shown) so the total counts were simply combined in the figures.
Preparation of monoclonal antibodies Monoclonal antibodies were made against radiochemically produced adducts of EF5 and thiol-containing proteins as described previously (Lord et al., 1993 
Results
Under conditions of extreme hypoxia and over a drug concentration range of 4-100AM, the 9L cell line showed a 2-3-fold increased rate of '4C-labelled EF5 binding compared with the WNRE cell line (Figure 1) (Figure 2) . The low level of fluorescence seen at relatively high oxygen levels is caused both by low levels of actual drug adducts (see Figure 1 ) and residual non-specific binding of the ELK3-51 antibody (see curve for cells incubated without drug). These conclusions arise from the observations that antibody-stained, non-drug treated cells always had a lower level of fluorescence than EF5-treated cells in air, but that cells not stained by the antibody (whether drug-treated or not) had a still lower level of fluorescence (data not shown).
The oxygen dependence of binding was the same using assays based on either radioactive drug uptake or antibody staining (Figures 3 and 4) . For measurement of binding of 14C-labelled EF5 cells were lysed and analysed after about 30 min of rinsing following exposure to drug; however, the antibody measurement technique required extensive time after drug exposure for fixation, blocking, staining and rinsing in solutions containing a mild detergent (0.3% Tween 20). Therefore, it was of interest to measure the loss of radioactive drug metabolites under the same conditions used to effect the antibody staining. We found that more than 50% of the acid precipitable radioactive counts remained with the cells during the antibody staining procedure, while most of the acid soluble counts were lost (data not shown). Thus, although clearly some antigen is lost, this loss appears to be very reproducible and may be associated with drug binding to relatively low molecular weight molecules (work in progress).
Representative flow cytometry of cells obtained from a tumour treated in vivo with EF5 ( Figure 5 ) showed a range of binding which was very similar, on an absolute basis, to the range observed for cells handled entirely in vitro, if allowance is made for the somewhat smaller cells from tumours and the pharmacological decay of drug in vivo. One difference was intensity (-) and radioactive drug uptake (0) for WNRE cells incubated with 1I00 jM EF5 for 3 h at the indicated oxygen partial pressures. Data were normalised to 0.6 under conditions of very low oxygen to move points from axis. The lowest oxygen levels plotted are about 0.01%, which is the maximwn oxygen in the gas phase of the chambers after the 3 h incubation period. 
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Log fluorescence intensity (Chapman et al., 1983; Koch et al., 1984) . The 9L line demonstrated first-order kinetics (rate of binding increased directly with misonidazole concentration) and was not very sensitive to very low oxygen levels (Koch, 1990) . These very low oxygen concentrations (below 0.1% oxygen) do not modify the radiation response, so variations in binding in this region of oxygen concentration can produce a highly inaccurate estimate of the radiation resistance. Indeed, extremely hypoxic cells may not be viable in vivo, so high binding for extremely vs moderately hypoxic cells is undesirable. The details of this relationship remain to be determined however, and may in fact be different for different tumours. Our current research is directed at testing the hypothesis that the assay of binding of EF5 can predict for the hypoxic fraction, and hence radiation resistance, of individual tumours. The results presented here show that this may be possible using relatively simple flow cytometric techniques. For cells disaggregated from 9L tumours, both the relative and absolute amount of binding were similar to values obtained in vitro, if we consider that the cells from tumours were somewhat smaller and had a smaller overall drug exposure (caused by drug distribution and half-life effects). Both factors contribute a factor of about 0.5. Furthermore, the tissue sections from the same tumour showed large regions of very bright binding with varying patterns (see accompanying manuscript). Some but not all of these patterns were consistent with the capillary diffusion model of Thomlinson and Gray (1955) . The large dynamic range of the drug-antibody detection scheme shows that there is a continuous distribution of binding throughout the tumour.
Although this is what should be expected of the oxygen distribution, it is more common to think of tumours as having an 'aerobic' and 'hypoxic' fraction. Other patterns of drug binding have not previously been observed, namely large fields with high to very high binding throughout. This is not unique to the 9L tumours grown as epigastric tissue isolates, and similar results have been found in subcutaneous 9L tumours as well as FSall tumours in mice (Evans et al., 1994; Koch et al., 1995) .
The present results suggest that binding of EF5 can be assessed quantitatively using immunofluorescent techniques; thus it will be possible to test for inter-and intra-tumour heterogeneity of bound EF5 using simple biopsy techniques and flow cytometric analysis. The capability of using flow cytometry techniques will then allow the simultaneous assay of many other important tumour/host cell properties. In addition, the use of fluorescence immunohistochemical techniques allows for the very rapid analysis of the distribution of EF5 binding in any normal/tumour tissue of interest. Quantitation of the two-dimensional change in fluorescence intensity appears very possible, requiring only a reliable light source and/or fluorescence standard coupled with the digital analysis of fluorescence intensity. Current work is moving from the use of a slide-film intermediate to direct digital image acquisition (Xillix Technologies, Vancouver, British Columbia, Canada). Thus, we anticipate that the direct test of the above-mentioned hypothesis is within reach.
